Yes... we know that those sucking down the MAGA nonsense are the most likely to take totally ineffective treatments for Covid. Hence the Covid death rate in red counties being much greater than blue counties. Ivermectin and hydroxychloroquine more likely to be prescribed in Republican counties, study finds https://www.marketwatch.com/story/i...n-republican-counties-study-finds-11645209818 Study: Political affiliation spurred hydroxychloroquine, ivermectin use for COVID-19 https://www.upi.com/Health_News/202...se-political-affiliation-study/6211645196231/
Another study showing what all the other mainstream studies have demonstrated -- Ivermectin is useless for preventing or treating Covid-19. Ivermectin doesn’t prevent severe disease from Covid-19, new study finds https://www.cnn.com/2022/02/18/health/ivermectin-severe-covid-19/index.html
This isn't science, study with 30 participants done by some third world country or data from Brazil's government is how one does science in the Magatard world.
Groups of contrarian physicians have emerged to promote “cures” without adding any evidence, and despite names like “America’s Front Line Doctors” and “Front Line COVID-19 Critical Care Alliance,” their members often do not work clinically — meaning they do not actually have credentials to practice medicine in any hospital settings — and do not treat Covid-19 patients. The founder of FLCCC, who is not currently affiliated with any health care institutions, recently disclosed that he and his family came down with coronavirus despite taking his unproven ivermectin protocol. The AFLD is actually selling ivermectin prescriptions online, a conflict of interest. True believers have turned to livestock preparations, which can be obtained at feed stores and other places that sell animal supplies without a prescription and without any oversight. And now poison control centers across the country are being overwhelmed with calls related to this off-label ivermectin use, because like most drugs that are used to kill pathogens, ivermectin can also easily be toxic to human life. Animal formulations, which are not FDA approved, usually contain higher concentrations and doses, making it much easier to get sick. But even human doses of ivermectin can have significant side effects and interactions. Not only are people poisoning themselves, there are now shortages of ivermectin for its legitimate uses and prices have skyrocketed. https://www.nbcnews.com/think/opini...-deadly-distractions-why-can-t-we-ncna1277830
So some TV show in Australia shows a graphic of Ivermectin while talking about the Queen's Covid case.... and the anti-vax Covid-denier community goes apeshit claiming the Queen is taking Ivermectin. Hint: She is not. How the Queen of England got roped into a horse paste-COVID scandal A news report inadvertently showed a one-second clip of the drug Ivermectin. https://www.dailydot.com/debug/queen-england-ivermectin-covid/
Ivermectin fails another COVID trial as study links use to GOP politics "Political affiliation should not be a factor in clinical treatment decisions." https://arstechnica.com/science/202...vid-trial-as-study-links-use-to-gop-politics/ The antiparasitic drug ivermectin failed to treat COVID-19 in yet another randomized clinical trial, but the drug remains popular amid the pandemic thanks to Republican politics. That's the takeaway from two separate studies published Friday in JAMA Internal Medicine. Together, the studies raise yet more concerns for the use of ivermectin against the pandemic virus—as well as the reasons behind its use, which appear politically motivated. "Political affiliation should not be a factor in clinical treatment decisions," the Harvard researchers behind one of the studies concluded. "Our findings raise concerns for public trust in a non-partisan health care system." Political sway The study began when researchers led by Harvard health policy researcher Michael Barnett took note of the sharp increase in prescriptions for ivermectin during the pandemic despite evidence that the drug is ineffective at treating COVID-19. The researchers set out to see if prescription levels could be linked with county-level political voting patterns in the 2020 US presidential election. For comparison, they also looked at the prescribing patterns for another antiparasitic drug called albendazole as well as the immunosuppressive drug methotrexate. Barnett and colleagues reviewed medical claims from more than 18.5 million adults to assess prescribing practices in counties across the US from January 2019 to December 2020. They then sorted counties into four groups based on their share of Republican votes, with the first quartile having the lowest share of Republican votes and the fourth having the highest Overall ivermectin prescribing increased 964 percent in December 2020 compared with prepandemic prescription levels in 2019. But those December 2020 prescriptions weren't evenly distributed; the counties with the highest shares of Republican votes had the highest levels of ivermectin prescribing. In fact, the higher the share of Republican votes in a county, the higher the level of ivermectin prescribing. The authors saw a similar pattern with hydroxychloroquine after the Food and Drug Administration revoked an emergency use authorization for use against COVID-19 in March 2020. Use of the immunosuppressive drug increased in the later half of 2020, with the highest prescribing in counties with the highest shares of Republican votes. Meanwhile, there were no such politically linked trends or changes in prescription levels for the two control drugs, methotrexate and albendazole. "Our findings are consistent with the hypothesis that US prescribing of hydroxychloroquine and ivermectin during the COVID-19 pandemic may have been influenced by political affiliation," Barnett and his colleagues concluded. The findings add context to the continued use of ivermectin for COVID-19, even as evidence continues to mount finding that the drug is ineffective and potentially dangerous. Failed trial Alongside Barnett's study, researchers in Malaysia reported results from a randomized clinical trial involving 490 high-risk COVID-19 patients. In the trial, ivermectin failed to prevent COVID-19 from progressing to severe disease in these high-risk patients. It also failed to make any statistically significant difference in a variety of COVID-19 outcomes, including timing of disease progression, length of hospital stay, the need for mechanical ventilation, the need for intensive care, and death. In Malaysia, people are required to report cases of COVID-19 to authorities, and people at risk of disease progression are either referred to the hospital or admitted to a COVID-19 quarantine center. That all made it easier to closely track trial participants. The trial enrolled people who were COVID-19 positive, age 50 or older, and had at least one underlying medical condition. At the time of enrollment, the 490 patients were considered to have mild to moderate infections. From there, 241 were randomly assigned to get oral ivermectin for five days, and 249 were randomly assigned to get standard care. At the end of the study, 52 of the 241 patients who received ivermectin (21.6 percent) had progressed to severe disease, while 43 of the 249 patients who just received standard care (17.3 percent) progressed. While there were no significant differences in other disease outcomes, the researchers did document more side effects in the ivermectin group. Overall, 44 patients reported side effects, with 33 of them being in the ivermectin group. Diarrhea was the most common side effect, which ivermectin is known to cause. There were also five cases of severe adverse reactions, four of which were in the ivermectin group. Two patients in the ivermectin group had heart attacks, one had severe anemia, and one developed hypovolemic shock as a result of severe diarrhea. The one remaining severe reaction in the control group involved abdominal bleeding. Not the first time While some early clinical work had suggested ivermectin may be effective for treating COVID-19, experts have since noted methodological weaknesses in those studies. Moreover, the findings in the Malaysia trial echo two other randomized clinical trials, in Colombia and Argentina. These trials also found no benefit to using ivermectin to improve COVID-19 symptoms or reduce hospitalization rates. Overall, the authors of the Malaysian trial conclude that, in their "randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19."
No surprise among rational people... Surprise! Study shows Ivermectin makes suffering from COVID worse A recent study published in the peer-reviewed journal JAMA Internal Medicine confirms that not only does Ivermectin not help you recover from/fight off COVID-19, but you may end up with some pretty severe side effects. https://boingboing.net/2022/02/19/s...rmectin-makes-suffering-from-covid-worse.html
Evidence Still Lacking to Support Ivermectin as Treatment for COVID-19 https://www.factcheck.org/2022/03/s...support-ivermectin-as-treatment-for-covid-19/ SciCheck Digest Randomized controlled trials haven’t found ivermectin is beneficial in treating COVID-19, although results for ongoing studies will provide a more definitive answer. Yet, a video presents two weak studies as “powerful” and “overwhelming” evidence that the medication works to combat COVID-19. Full Story After more than 80 studies have evaluated the use of ivermectin, an antiparasitic medication, to treat or prevent COVID-19 in humans, the National Institutes of Health, the Centers for Disease Control and Prevention and the World Health Organization have determined there is insufficient evidence to recommend using ivermectin to treat COVID-19. As we’ve reported, large clinical trials to determine its safety and effectiveness are ongoing, and results are expected in about a month. But so far, randomized controlled trials have shown no evidence of a clinical benefit for ivermectin. And the medication has not been approved or authorized by the Food and Drug Administration to prevent or treat COVID-19. Yet, some people keep touting the effectiveness of the medication against COVID-19. In February, we fact-checked a misleading claim about ivermectin and the NIH, as well as false claims that a Japanese company had found ivermectin had worked in a phase 3 clinical trial, which was based on an inaccurate news article. On March 6, John Campbell, who has a doctorate in nursing education but is not a physician, posted a video about the drug that amassed nearly a million views. It incorrectly presented two weak studies as “powerful” and “overwhelming” evidence that the drug works to combat the disease. “Why isn’t this in the newspapers?” Campbell asks his viewers after reviewing preliminary results of a study that was later canceled by its authors and the results of a flawed study. “This is why I think ivermectin is going to be one of the big scandals of this [pandemic]. It’s almost as if information has been deliberately suppressed throughout the pandemic, to be quite honest.” On March 14, Campbell replaced the original video with a new version that eliminates the discussion of the first study. Information on the ongoing and completed studies on ivermectin has been widely available, and the public can access the information on the NIH website. The studies Campbell highlights are not in the news because both have significant limitations and are not randomized controlled trials, which are considered the gold standard of clinical research. Such trials randomly assign participants to treatment or control groups, enabling researchers to more confidently evaluate whether a treatment led to different results. We reached out to Campbell to ask why he didn’t include important context about the two studies — and why he omitted mention of stronger evidence from randomized controlled trials that have not found ivermectin to be helpful with COVID-19. But we did not hear back from him. In his latest video, Campbell said he deleted his March 6 video from his YouTube channel because one of the two studies featured in that video was “flawed.” The new video, however, still shows original footage from the March 6 video of Campbell discussing the second study, which as we’ll explain later, has significant problems. Campbell’s original video still remains in other forms on Facebook and YouTube. One of the latest results from a randomized clinical trial published in JAMA Internal Medicine on Feb. 18 came from Malaysia. The study found that treatment with ivermectin during the early stages of COVID-19 in 490 patients did not reduce the risk of progression to severe disease — 21.6% of the patients in the ivermectin group and 17.3% in the control group progressed to severe disease. Dr. Steven Chee Loon Lim, co-author of the study and an infectious disease physician at the Raja Permaisuri Bainun Hospital in Malaysia, told us in an email there were no “statistically significant effects in the rate of mechanical ventilation, ICU admission and mortality,” either. “Essentially, our study findings have dismissed the notion of ivermectin being a ‘miracle drug’ against COVID-19. Individuals infected with COVID-19 should not resort to self-medication with ivermectin. Having a false sense of recovery while taking an ineffective drug could lead to delay in seeking appropriate medical care, thus resulting in poorer outcomes,” Lim wrote. Results of other ongoing clinical trials with over 1,000 participants each are expected soon. Dr. David Boulware, a professor of medicine at the University of Minnesota Medical School and an adviser for two large trials in the U.S., told us in an email that multiple trials “may likely publicly report results in April.” Both the Together trial in Brazil and the University of Minnesota Covid-Out trial in the U.S. are fully completed, he said. The ACTIV-6 trial, funded by the NIH, has completed follow-up of its ivermectin arm, and data are being analyzed. And the PRINCIPLE trial in the United Kingdom and another one in Japan are still recruiting, he said. Preliminary Study Showed Association, Not Causality In his March 6 video, Campbell starts by reviewing an abstract presented at a virtual conference in November 2021 by researchers from the University of Miami. The authors retrospectively identified adults in the U.S. with a COVID-19 infection between Jan. 1, 2020, and July 11, 2021, using a large database of electronic health record information from a network of health care organizations. They then compared patients who had been treated with ivermectin (1,072 patients) with those who had been treated with remdesivir (40,536 patients), an FDA-approved antiviral treatment for hospitalized or high-risk non-hospitalized COVID-19 patients. They concluded ivermectin was associated with reduced mortality compared with remdesivir, with an odds ratio of 0.308. “In other words, you’re about 70% less likely to die if you take ivermectin compared to taking remdesivir,” says Campbell. “It’s pretty convincing data from national databases.” Others also have used the abstract on social media to argue that it means ivermectin is effective against COVID-19. But the authors of the study have said that’s not how the data should be interpreted. Dr. Jose Gonzales Zamora, a co-author of the study and associate program director of the infectious disease fellowship at the University of Miami, told us the preliminary results of the observational study only show a statistical association between reduced mortality and ivermectin treatment, not causality. In other words, ivermectin isn’t necessarily the reason why that group of patients fared better. “We can’t necessarily say, based on this kind of study, retrospective, that it was ivermectin what really reduced mortality because there are other confounding variables that could also affect that outcome,” Zamora said in a phone interview conducted in Spanish. “It is not correct to say ivermectin reduces mortality by 70%.” One of those confounding factors could be the age of the patients, he said, since the patients who received ivermectin were on average 10 years younger than those who were treated with remdesivir. (Even though the study tried to control for age and other factors using statistics, such adjustments in observational studies are imperfect and still at risk for bias.) Another limitation of the study, Zamora said, was that the authors didn’t know how ill patients were when they received treatment. Since remdesivir is approved for hospitalized and high-risk patients, he explained, it’s possible those patients were sicker than the patients who received ivermectin. The study is not proof of efficacy, Zamora said. And he clarified that the study shouldn’t be read as support for using ivermectin. Neither his research team nor his hospital had ever recommended the drug. One of the abstract’s most important conclusions — and one that Campbell omitted — Zamora pointed out, is that “further double-blinded placebo-controlled RCTs with large samples are required” to come to a definitive conclusion. Double-blinded randomized controlled trials are those in which neither the patients nor the researchers know which patients have been given the treatment versus the placebo while data is being collected. The study was never peer-reviewed and was halted. “We did not submit the manuscript for a reason, weak evidence,” said its lead author, Iakov Efimenko, on Twitter. Zamora added that continuing the study made no sense once the results of randomized clinical trials failed to find any clinical benefit of using ivermectin for COVID-19 patients. Insufficient Evidence from Flawed Study The second study Campbell presents in his video is a prospective, observational study done in the Brazilian city of Itajaí. Its authors include Dr. Pierre Kory, one of the strongest advocates of ivermectin in the U.S., and researchers in Brazil, Canada and Colombia — some of them also part of Kory’s pro-ivermectin nonprofit, called the Front Line COVID-19 Critical Care Alliance. The study concludes that the use of ivermectin reduced infections by half and reduced COVID-19 mortality and hospitalizations by 70% and 67%, respectively. “70% reduction in mortality in this study. I mean, this is just huge. And this is with a tiny dose of ivermectin every fortnight acting as a prophylactic, you know, why are people not talking about this?” Campbell says in his video. “The evidence just seems so powerful, present and overwhelming. I mean, 70%, how do you argue with a number like that?” But the study is not a randomized, double-blind, placebo-controlled clinical trial, and it has multiple limitations. Health Feedback fact-checked stories published by the Gateway Pundit, Zero Hedge and the Blaze about an earlier draft of the study that was posted as a preprint in December. “The study contained multiple methodological flaws that call the reliability of its conclusions into question. For example, there are indications that many people assigned to the ivermectin treatment group didn’t take the drug consistently, or stopped taking it after a while. It is therefore unclear whether any observed effect in this group can be reliably attributed to ivermectin treatment,” Health Feedback concluded. In a Twitter thread on Dec. 15, epidemiologist Gideon Meyerowitz-Katz detailed some of the study’s problems, including conflicts of interest and lack of controls for important confounders, such as variables that could increase the risk of getting COVID-19. The study was then peer-reviewed and published on Jan. 15 in Cureus, an open access online medical journal that allows researchers to publish studies for free and faster than the traditional peer-reviewed journals — 11 days in this case. But some of the problems remain, as PolitiFact.com explained. The study analyzed data of a citywide COVID-19 prevention program using ivermectin in Itajaí, Brazil, from July to December 2020, when vaccines were not available. The whole population of the city was offered ivermectin, to be taken for two consecutive days every 15 days. Out of 159,561 residents, 113,845 used ivermectin and 45,716 did not. But according to a statement released by the city of Itajaí in January 2021, the numbers of voluntary users fell with time — 138,216 took the first dose; two weeks later 93,970 took the second and third doses, and only 8,312 took the fourth and fifth. “That is, there was no biweekly continuity of the use of ivermectin, as recommended,” the statement said. A list of the authorized studies in Brazil using ivermectin as treatment for COVID-19 — provided to the Brazilian fact-checking coalition Comprova by the Brazilian National Research Ethics Commission — said the study “was registered with a sample of 9,956 participants.” As we said, results of multiple large clinical trials on the safety and efficacy of the use of ivermectin to treat COVID-19 will be available in the coming months. They will provide a more definitive answer as to whether ivermectin is beneficial, or not, in treating COVID-19 patients. But for now, studies haven’t found the drug to be beneficial, and health officials have warned people not to self-medicate. Editor’s note:SciCheck’s COVID-19/Vaccination Project is made possible by a grant from the Robert Wood Johnson Foundation. The foundation has no control over our editorial decisions, and the views expressed in our articles do not necessarily reflect the views of the foundation. The goal of the project is to increase exposure to accurate information about COVID-19 and vaccines, while decreasing the impact of misinformation. Sources COVID-19 Treatment Guidelines. Ivermectin. NIH. Updated 11 Feb 2021. “Ivermectin Products are Not Approved by FDA to Prevent or Treat COVID-19.” CDC Clinician Outreach and Communication Activity. Newsletter. “WHO advises that ivermectin only be used to treat COVID-19 within clinical trials.” WHO Newsroom. 31 Mar 2021. Jaramillo, Catalina. “Ongoing Clinical Trials Will Decide Whether (or Not) Ivermectin Is Safe, Effective for COVID-19.” FactCheck.org. Updated 29 Oct 2021. “Early Treatment of COVID-19 with Repurposed Therapies: The TOGETHER Adaptive Platform Trial.” Together Clinical Trials. PowerPoint presentation. 6 Aug 2021. Clinical Trials.gov. National Institutes of Health. Accessed 11 Mar 2022. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. Food and Drug Administration. Updated 10 Dec 2021, accessed 14 Mar 2022. Jones, Brea. “Facebook Post Misleads on NIH’s Position on Ivermectin.” FactCheck.org. 8 Feb 2022. Gore, D’Angelo. “Social Media Posts Repeat Inaccurate Reporting on Ivermectin and Omicron.” FactCheck.org. 2 Feb 2022. John Campbell profile. Linkedin. Accessed 14 Mar 2022. Lim, Steven Chee Loon, et al. “Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities. The I-TECH Randomized Clinical Trial.” JAMA Internal Medicine. 18 Feb 2022. Lim, Steven Chee Loon. Infectious disease physician at the Raja Permaisuri Bainun Hospital in Malaysia. Email correspondence with FactCheck.org. 8 Mar 2022. Boulware, David. Professor of medicine at the University of Minnesota Medical School. Email correspondence with FactCheck.org. 8 Mar 2022. Efimenko, Iakov, et al. “Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database.” International Journal of Infectious Diseases. Volume 116, Supplement. Mar 2022. “Florida study Ivermectin misinformation from Kory, Campbell, and Peterson.” Botioech and Bioinformatics with Prof. Greg. You Tube video. 9 Mar 2022. Efimenko, Iakov. “Hi Dr. Peterson, first author of the paper, I think the information and data is being crudely misrepresented and misinterpreted. This is an abstract (NOT PEER REVIEWED) from a conference I presented at. We did not submit the manuscript for a reason, weak evidence.” Twitter. 8 Mar 2022. Gonzales Zamora, Jose. Associate program director of the infectious disease fellowship at the University of Miami. Phone interview with FactCheck.org. 8 Mar 2022. Kerr, Lucy, et al. “Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching.” Cureus. 15 Jan 2022. Fiore, Kristina. “Doc Took ‘Miracle Drug’, Still Got COVID; St. Jude Has Billions as Families Go Broke.” MedpageToday. 17 Nov 2021. Teoh, Flora. “Ivermectin study in the city of Itajaí contains several methodological weaknesses, resulting in questionable conclusions.” Health Feedback. 12 Dec 2021. Meyerowitz-Katz, Gideon. “5/n So, on to the problems. There are quite a few. Firstly, the author group. While this is not disclosed in the paper, several authors are members of the FLCCC, an ivermectin promotion organisation who we might expect to have some interest in the outcome of the research.” Twitter thread. 15 Dec 2021. Colliver, Victoria. “Medical journal uses crowdsourcing model.” SFGate. 18 Dec 2012. Cercone, Jeff. “Study in Brazil on ivermectin as a COVID-19 prevention is flawed, experts say.” PolitiFact. 28 Jan 2022. “Nota de esclarecimento – tratamentos profiláticos.” Municipio de Itajai. Press release. 21 Jan 2021. “Estudio feito em Itajai nao prova eficacia de ivermectina contra covid-19.” Comprova. 3 Mar 2022.
“Researchers testing repurposed drugs against Covid-19 found that ivermectin didn’t reduce hospital admissions, in the largest trial yet of the effect of the antiparasitic on the disease driving the pandemic,” the Wall Street Journal reports.
The stories that I have heard are very positive for the use of Ivermectin during early phases of Kung Flu. And no---Human Ivermectin is not horse dewormer.